Royalty Pharma plc (RPRX)
Last Price$33.90.6%
Market Cap$15.2B
RPRX Rating
RPRX Quality rating performance
RPRX Intrinsic Value
Key Highlights:
As of Mar 03, 2025 RPRX Relative Value is $60.2, which is undervalued by 77.8%, compared to current share price of $33.9.
As of Mar 03, 2025 RPRX DCF Value is $299.4, which is undervalued by 784.5%, compared to current share price of $33.9.
RPRX Share Price History
1W 0.1%
1M 8.0%
6M 18.2%
YTD 23.5%
1Y 15.9%
3Y (5.7%)
5Y (16.1%)
10Y (16.1%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
RPRX Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$15.2B
$14.3B
$2,263.9M
$2,769.5M
Shares Outstanding
449M
Employees
99
Growth (CAGR)
4.5%
(13.2%)
(19.01%)
10.6%
35.2%
132.66%
Profitability
73.9%
57.1%
37.9%
122.7%
122.3%
Intrinsic Value
$179.7 (430.9% undervalued)
$299.5
$59.9
$122.1
$276.8
121.4%
Return on Capital
Financial Health
($929.0M)
(0.3x)
5.7x
Dividends
(15.1%)
2.5%
13.6%
Feb 21, 2025
Earnings
May 07, 2025
MISS by (23.4%)
BEAT by 10.8%
(7.1%)
6 Beat & 4 Miss
RPRX Stock Financials
RPRX Income Statement Metrics
Annual
Quarterly
LTM
RPRX Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$2,769.0M -7.2% YoY
Capital Expenditure (CAPEX)
$0.0 -100.0% YoY
Free Cash Flow (FCF)
$2,769.0M +215.8% YoY
RPRX Income Statement Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
$2,264.0M (3.8%) YoY
Pre-tax income
$1,331.0M (21.7%) YoY
58.8% margin
RPRX Balance Sheet Overview
Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Dec'24
Assets
Liabilities
Total assets
$18.2B
Current assets ($1,802.1M, 9.9% of total)
$987.2M (5.4%)
$27.0M (0.1%)
Other current assets
$788.0M (4.3%)
Non-current assets ($16.4B, 90.1% of total)
$187.0M (1.0%)
$0.0 (0.0%)
$0.0 (0.0%)
Other non-current assets
$16.2B (89.1%)
Financial position
$6,625.2M
Cash & Short-term
Investments
Total Debt
RPRX Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
RPRX Earnings Surprises
Crunching data... Almost there!
RPRX Dividends
RPRX Dividend Yield
Crunching data... Almost there!
RPRX Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with RPRX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$15.2B | 5.6 | $179.7 430.9% undervalued | 15.9% | $2,263.9M | $2,769.5M | (3.8%) | 122.3% | 73.9% | 14.5% | 0.0% | |
$402.0B | 6.7 | $60.0 32.9% overvalued | (29.6%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$125.5B | 5.7 | $195.0 59.6% overvalued | 14.0% | $11.0B | ($790.3M) | 11.5% | (7.2%) | 86.1% | (15.0%) | 10.7% | |
$74.0B | 6.5 | $1,013.8 48.0% undervalued | (29.5%) | $14.2B | $3,597.2M | 8.3% | 25.3% | 86.7% | 25.0% | 5.7% | |
$38.1B | 5.8 | $109.1 82.5% overvalued | 59.5% | $2,258.9M | ($211.2M) | 127.3% | (9.4%) | 86.8% | (41.3%) | N/A | |
$31.3B | 5.2 | $93.6 61.6% overvalued | 62.3% | $2,248.2M | ($42.6M) | 23.0% | (1.9%) | 85.6% | (7.2%) | 1,931.9% | |
$27.1B | 6.3 | $165.8 48.6% undervalued | 24.9% | €3,040.1M | €985.3M | (54.1%) | 32.4% | 84.3% | (41.4%) | 1.3% | |
$14.8B | 5.6 | $46.7 33.6% overvalued | 17.6% | $4,241.2M | $235.2M | 14.8% | 5.5% | 92.3% | (12.7%) | 1.3% | |
$14.6B | 5.9 | $0.5 97.4% overvalued | 327.0% | $0.0 | ($142.1M) | N/A | N/A | N/A | (3,335.4%) | 1.9% | |
$14.0B | 7.7 | $427.2 37.8% undervalued | 35.5% | $2,877.4M | $1,080.6M | 23.6% | 37.6% | 89.2% | 65.4% | 4.7% | |
$1,846.9M | 5.4 | $2,805.1 1,137.3% undervalued | 39.9% | $3,316.8M | ($1,009.2M) | 50.5% | (30.4%) | 83.1% | (38.4%) | 32.1% |
FAQ
What is Royalty Pharma plc (RPRX) stock rating?
As of today, Royalty Pharma plc has a stock rating of 6 (out of 10), which is considered Good.
is Royalty Pharma plc (RPRX) a good stock to buy?
As of today, Royalty Pharma plc has a Good stock rating, which is 430.9% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.